Pembrolizumab + Defactinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Conditions
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial Timeline
Jun 4, 2019 → Jan 15, 2025
NCT ID
NCT03727880About Pembrolizumab + Defactinib
Pembrolizumab + Defactinib is a phase 2 stage product being developed by Merck for Resectable Pancreatic Ductal Adenocarcinoma (PDAC). The current trial status is completed. This product is registered under clinical trial identifier NCT03727880. Target conditions include Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04201145 | Phase 1 | Withdrawn |
| NCT03727880 | Phase 2 | Completed |
Competing Products
20 competing products in Resectable Pancreatic Ductal Adenocarcinoma (PDAC)